当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

Abstract：

:8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and non-Hodgkin's lymphoma with chromosomal translocations fusing several genes, most commonly ZNF198, to fibroblast growth factor receptor-1 (FGFR1). However, patients with BCR-FGFR1 fusion present with typical chronic myeloid leukemia (CML). We demonstrate that ZNF198-FGFR1 induces EMS-like disease in mice, with myeloproliferation and T lymphoma arising from common multipotential progenitors. Mutation of FGFR1 Tyr766 attenuates both myeloid and lymphoid diseases, identifying phospholipase C-gamma1 as a downstream effector. Bcr-FGFR1 binds Grb2 via Bcr Tyr177 and induces CML-like leukemia in mice, whereas Bcr-FGFR1/Y177F lacks Grb2 binding and causes EMS-like disease. These results implicate different signaling pathways originating from both kinase and fusion partner in the pathogenesis of CML and EMS.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Roumiantsev S,Krause DS,Neumann CA,Dimitri CA,Asiedu F,Cross NC,Van Etten RA

doi

10.1016/s1535-6108(04)00053-4

keywords:

subject

Has Abstract

pub_date

2004-03-01 00:00:00

pages

287-98

issue

3

eissn

1535-6108

issn

1878-3686

pii

S1535610804000534

journal_volume

5

pub_type

杂志文章

相关文献

CANCER CELL文献大全
  • Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.

    abstract：:Adaptive chemoresistance and consequent tumor recurrence present major obstacles to the improvement of the prognosis and quality-of-life of patients with advanced-stage ovarian cancer. In this issue of Cancer Cell, Yu and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2015.06.008

    authors： Wei W,Birrer MJ

    更新日期：2015-07-13 00:00:00

  • SnapShot: Immune Checkpoint Inhibitors.

    abstract：:Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understa...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.05.010

    authors： Abril-Rodriguez G,Ribas A

    更新日期：2017-06-12 00:00:00

  • c-Raf in KRas Mutant Cancers: A Moving Target.

    abstract：:Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affec...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2018.01.017

    authors： McCormick F

    更新日期：2018-02-12 00:00:00

  • Wild-type RAS: keeping mutant RAS in CHK.

    abstract：:Mutant RAS-driven tumorigenesis was thought for decades to arise independently of wild-type RAS isoforms, but recent evidence indicates wild-type isoforms are involved. In this issue of Cancer Cell, Grabocka and colleagues report how the loss of wild-type RAS alters oncogenic signaling and dampens the DNA-damage respo...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2014.01.029

    authors： Anastassiadis T,Brown EJ

    更新日期：2014-02-10 00:00:00

  • Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia.

    abstract：:Through in silico and other analyses, we identified FOXC1 as expressed in at least 20% of human AML cases, but not in normal hematopoietic populations. FOXC1 expression in AML was almost exclusively associated with expression of the HOXA/B locus. Functional experiments demonstrated that FOXC1 contributes to a block in...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.07.017

    authors： Somerville TD,Wiseman DH,Spencer GJ,Huang X,Lynch JT,Leong HS,Williams EL,Cheesman E,Somervaille TC

    更新日期：2015-09-14 00:00:00

  • Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization.

    abstract：:Metastases arising from tumors have the proclivity to colonize specific organs, suggesting that they must rewire their biology to meet the demands of the organ colonized, thus altering their primary properties. Each metastatic site presents distinct metabolic challenges to a colonizing cancer cell, ranging from fuel a...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2018.02.001

    authors： Schild T,Low V,Blenis J,Gomes AP

    更新日期：2018-03-12 00:00:00

  • The potential of new tumor endothelium-specific markers for the development of antivascular therapy.

    abstract：:Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anticancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium have been identified during the last decade. However, due to the expression in both physiological and tumor angiogenesis, only a ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2007.05.004

    authors： Li JL,Harris AL

    更新日期：2007-06-01 00:00:00

  • Chemokine to the rescue: interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer.

    abstract：:Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion....

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.11.012

    authors： Abraham RT

    更新日期：2012-12-11 00:00:00

  • A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

    abstract：:Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mT...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.01.014

    authors： Fan Q,Aksoy O,Wong RA,Ilkhanizadeh S,Novotny CJ,Gustafson WC,Truong AY,Cayanan G,Simonds EF,Haas-Kogan D,Phillips JJ,Nicolaides T,Okaniwa M,Shokat KM,Weiss WA

    更新日期：2017-03-13 00:00:00

  • Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.

    abstract：:Loss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced tum...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.11.014

    authors： Schwitalla S,Ziegler PK,Horst D,Becker V,Kerle I,Begus-Nahrmann Y,Lechel A,Rudolph KL,Langer R,Slotta-Huspenina J,Bader FG,Prazeres da Costa O,Neurath MF,Meining A,Kirchner T,Greten FR

    更新日期：2013-01-14 00:00:00

  • In Search of a Cure for Proteostasis-Addicted Cancer: A AAA Target Revealed.

    abstract：:Tumorigenesis is often associated with an unbalanced protein homeostasis (proteostasis) network, which sensitizes cancer cells to drugs targeting protein quality control (PQC) regulators. In this issue of Cancer Cell, Anderson and colleagues investigated the anti-cancer activity of a new class of inhibitor against a m...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2015.10.006

    authors： Xia D,Ye Y

    更新日期：2015-11-09 00:00:00

  • Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.

    abstract：:ARID1A encodes an SWI/SNF chromatin-remodeling factor and is frequently mutated in various cancers. This study demonstrates that ARID1A-deficient cancer cells are specifically vulnerable to inhibition of the antioxidant glutathione (GSH) and the glutamate-cysteine ligase synthetase catalytic subunit (GCLC), a rate-lim...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.12.009

    authors： Ogiwara H,Takahashi K,Sasaki M,Kuroda T,Yoshida H,Watanabe R,Maruyama A,Makinoshima H,Chiwaki F,Sasaki H,Kato T,Okamoto A,Kohno T

    更新日期：2019-02-11 00:00:00

  • Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor.

    abstract：:Oncoproteins and tumor suppressors antagonistically converge on critical nodes governing neoplastic growth, invasion, and metastasis. We discovered that phosphorylation of the ETS1 and ETS2 transcriptional oncoproteins at specific serine or threonine residues creates binding sites for the COP1 tumor suppressor protein...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2014.06.026

    authors： Lu G,Zhang Q,Huang Y,Song J,Tomaino R,Ehrenberger T,Lim E,Liu W,Bronson RT,Bowden M,Brock J,Krop IE,Dillon DA,Gygi SP,Mills GB,Richardson AL,Signoretti S,Yaffe MB,Kaelin WG Jr

    更新日期：2014-08-11 00:00:00

  • Rab1A is an mTORC1 activator and a colorectal oncogene.

    abstract：:Amino acid (AA) is a potent mitogen that controls growth and metabolism. Here we describe the identification of Rab1 as a conserved regulator of AA signaling to mTORC1. AA stimulates Rab1A GTP binding and interaction with mTORC1 and Rheb-mTORC1 interaction in the Golgi. Rab1A overexpression promotes mTORC1 signaling a...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.09.008

    authors： Thomas JD,Zhang YJ,Wei YH,Cho JH,Morris LE,Wang HY,Zheng XF

    更新日期：2014-11-10 00:00:00

  • Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.

    abstract：:The tumor suppressor cylindromatosis (CYLD) inhibits the NFκB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.04.026

    authors： Nikolaou K,Tsagaratou A,Eftychi C,Kollias G,Mosialos G,Talianidis I

    更新日期：2012-06-12 00:00:00

  • Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.

    abstract：:Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2020.10.008

    authors： Zhao W,Li J,Chen MM,Luo Y,Ju Z,Nesser NK,Johnson-Camacho K,Boniface CT,Lawrence Y,Pande NT,Davies MA,Herlyn M,Muranen T,Zervantonakis IK,von Euw E,Schultz A,Kumar SV,Korkut A,Spellman PT,Akbani R,Slamon DJ,Gray

    更新日期：2020-12-14 00:00:00

  • A New Role for Lyn in the CLL Microenvironment.

    abstract：:The role of Lyn, both a positive and a negative regulator of B and myeloid cells, in chronic lymphocytic leukemia (CLL) has not been well characterized. In this issue of Cancer Cell, Nguyen et al. demonstrated that Lyn in macrophages rather than in CLL cells is critical for the malignancy. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.09.018

    authors： Dong S,Byrd JC

    更新日期：2016-10-10 00:00:00

  • Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.

    abstract：:Recent studies have identified genes and core pathways that are altered in human glioblastoma. However, the mechanisms by which alterations of these glioblastoma genes singly and cooperatively transform brain cells remain poorly understood. Further, the cell of origin of glioblastoma is largely elusive. By targeting a...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.04.001

    authors： Wang Y,Yang J,Zheng H,Tomasek GJ,Zhang P,McKeever PE,Lee EY,Zhu Y

    更新日期：2009-06-02 00:00:00

  • Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia.

    abstract：:Targeting chromatin regulators for the treatment of malignancies has shown great promise, but also revealed significant challenges. By employing an elegant shRNA screen and a selective pharmacological inhibitor, a recent study published in Nature establishes the bromodomain protein Brd4 as novel target in acute myeloi...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.08.019

    authors： Blobel GA,Kalota A,Sanchez PV,Carroll M

    更新日期：2011-09-13 00:00:00

  • Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability.

    abstract：:In this study, we show that the formation of polyploidy following sustained mitotic checkpoint activation appears to be preceded by the ubiquitin-dependent proteolysis of hBubR1. In addition, the level of hBubR1 is significantly reduced not only in polyploid cells created by sustained mitotic spindle damage, but also ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/s1535-6108(03)00302-7

    authors： Shin HJ,Baek KH,Jeon AH,Park MT,Lee SJ,Kang CM,Lee HS,Yoo SH,Chung DH,Sung YC,McKeon F,Lee CW

    更新日期：2003-12-01 00:00:00

  • A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

    abstract：:Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissect...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.10.018

    authors： Mok SC,Bonome T,Vathipadiekal V,Bell A,Johnson ME,Wong KK,Park DC,Hao K,Yip DK,Donninger H,Ozbun L,Samimi G,Brady J,Randonovich M,Pise-Masison CA,Barrett JC,Wong WH,Welch WR,Berkowitz RS,Birrer MJ

    更新日期：2009-12-08 00:00:00

  • Dangerous Liaisons: Deviant Endothelium NOTCHes toward Tumor Metastasis.

    abstract：:In this issue of Cancer Cell, Wieland et al. uncover a feedback loop in which tumor cells, by augmenting Notch signaling, provoke a senescent and pro-inflammatory state in endothelial cells, promoting neutrophil infiltration, tumor cell adhesion, and metastasis. Interfering with this Notch-dependent crosstalk may be a...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2017.02.016

    authors： Guo P,Rafii S

    更新日期：2017-03-13 00:00:00

  • Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice.

    abstract：:Expression of the cyclin-dependent kinase inhibitor p27(Kip1) (p27) is frequently reduced in human colorectal cancer, and this correlates with poor patient prognosis. To clarify the role of p27 in gastrointestinal (GI) cancer, we measured p27 expression, as well as the effect of germline deletion of p27, in 3 differen...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/s1535-6108(02)00054-5

    authors： Philipp-Staheli J,Kim KH,Payne SR,Gurley KE,Liggitt D,Longton G,Kemp CJ

    更新日期：2002-05-01 00:00:00

  • NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

    abstract：:Using sequential gene expression profiling (GEP) samples, we defined a major functional group related to drug resistance that contains chromosomal instability (CIN) genes. One CIN gene in particular, NEK2, was highly correlated with drug resistance, rapid relapse, and poor outcome in multiple cancers. Overexpressing N...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.12.001

    authors： Zhou W,Yang Y,Xia J,Wang H,Salama ME,Xiong W,Xu H,Shetty S,Chen T,Zeng Z,Shi L,Zangari M,Miles R,Bearss D,Tricot G,Zhan F

    更新日期：2013-01-14 00:00:00

  • PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia.

    abstract：:PML/RARalpha is of crucial importance in acute promyelocytic leukemia (APL) both pathologically and therapeutically. Using a genome-wide approach, we identified in vivo PML/RARalpha binding sites in a PML/RARalpha-inducible cell model. Of the 2979 targeted regions, >62% contained canonical PU.1 motifs and >84% of thes...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.12.045

    authors： Wang K,Wang P,Shi J,Zhu X,He M,Jia X,Yang X,Qiu F,Jin W,Qian M,Fang H,Mi J,Yang X,Xiao H,Minden M,Du Y,Chen Z,Zhang J

    更新日期：2010-02-17 00:00:00

  • Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.

    abstract：:In mice, Lkb1 deletion and activation of Kras(G12D) results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with Lk...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2010.04.026

    authors： Carretero J,Shimamura T,Rikova K,Jackson AL,Wilkerson MD,Borgman CL,Buttarazzi MS,Sanofsky BA,McNamara KL,Brandstetter KA,Walton ZE,Gu TL,Silva JC,Crosby K,Shapiro GI,Maira SM,Ji H,Castrillon DH,Kim CF,García-Echeve

    更新日期：2010-06-15 00:00:00

  • Strategies for p53 reactivation in human sarcoma.

    abstract：:Emerging strategies in cancer therapeutics link the genomic mutational and proteomic landscape, allowing intelligent reasoning on target selection. In this issue of Cancer Cell, Piccinin and colleagues use this approach to demonstrate that the mesenchymal protein Twist1 inhibits p53, providing a novel target for react...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.08.020

    authors： Hupp TR,Hayward RL,Vojtesek B

    更新日期：2012-09-11 00:00:00

  • A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

    abstract：:Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.013

    authors： Vidal SJ,Rodriguez-Bravo V,Quinn SA,Rodriguez-Barrueco R,Lujambio A,Williams E,Sun X,de la Iglesia-Vicente J,Lee A,Readhead B,Chen X,Galsky M,Esteve B,Petrylak DP,Dudley JT,Rabadan R,Silva JM,Hoshida Y,Lowe SW,Cordo

    更新日期：2015-02-09 00:00:00

  • Turning on a dimer: new insights into MLL chimeras.

    abstract：:In this issue of Cancer Cell, demonstrate a novel mechanism for the oncogenic activity of MLL chimeric proteins. By providing coiled-coil or other dimerization domains, the cytoplasmic partners of MLL fusion proteins donate a platform for MLL homodimerization, allowing recruitment of accessory factors needed to activa...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/s1535-6108(03)00192-2

    authors： Hsu K,Look AT

    更新日期：2003-08-01 00:00:00

  • Singling Out Chromosome Gains in Tumor Evolution.

    abstract：:In this issue of Cancer Cell, Sheltzer et al. shed new light on Theodor Boveri's century-old hypothesis by demonstrating that aneuploidy characterized by single-chromosome gains acts to suppress tumorigenesis and that aneuploidy itself is a nidus for genomic instability. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2017.01.011

    authors： Naylor RM,van Deursen JM

    更新日期：2017-02-13 00:00:00